321 related articles for article (PubMed ID: 30789111)
1. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
[TBL] [Abstract][Full Text] [Related]
2. IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
Gyldmark M; Lampe K; Ruof J; Pöhlmann J; Hebborn A; Kristensen FB
Int J Technol Assess Health Care; 2018 Jan; 34(5):458-463. PubMed ID: 30334508
[TBL] [Abstract][Full Text] [Related]
3. Early dialogue with health technology assessment bodies: a European perspective.
Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
[TBL] [Abstract][Full Text] [Related]
4. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
5. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality].
Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129
[TBL] [Abstract][Full Text] [Related]
6. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
Oortwijn W; Mathijssen J; Banta D
Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
[TBL] [Abstract][Full Text] [Related]
7. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
8. Shedding light on the HTA consultancy market: Insights from Poland.
Csanádi M; Ozierański P; Löblová O; King L; Kaló Z; Botz L
Health Policy; 2019 Dec; 123(12):1237-1243. PubMed ID: 31466804
[TBL] [Abstract][Full Text] [Related]
9. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
10. Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.
Kleijnen S; Pasternack I; Van de Casteele M; Rossi B; Cangini A; Di Bidino R; Jelenc M; Abrishami P; Autti-Rämö I; Seyfried H; Wildbacher I; Goettsch WG
Int J Technol Assess Health Care; 2014 Nov; 30(5):488-96. PubMed ID: 25747557
[TBL] [Abstract][Full Text] [Related]
11. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA.
Kristensen FB; Lampe K; Chase DL; Lee-Robin SH; Wild C; Moharra M; Garrido MV; Nielsen CP; Røttingen JA; Neikter SA; Bistrup ML;
Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():1-8. PubMed ID: 20030885
[TBL] [Abstract][Full Text] [Related]
12. The HTA Core Model
Kristensen FB; Lampe K; Wild C; Cerbo M; Goettsch W; Becla L
Value Health; 2017 Feb; 20(2):244-250. PubMed ID: 28237203
[TBL] [Abstract][Full Text] [Related]
13. The role of health technology assessment bodies in shaping drug development.
Ciani O; Jommi C
Drug Des Devel Ther; 2014; 8():2273-81. PubMed ID: 25419117
[TBL] [Abstract][Full Text] [Related]
14. Health technology assessment. The pharmaceutical industry perspective.
Schubert F
Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
[TBL] [Abstract][Full Text] [Related]
15. HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN EUROPE: PROCESSES, PRACTICES, AND METHODS.
Fuchs S; Olberg B; Panteli D; Busse R
Int J Technol Assess Health Care; 2016 Jan; 32(4):246-255. PubMed ID: 27670589
[TBL] [Abstract][Full Text] [Related]
16. Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective.
Kido K; Matsumaru N; Tsukamoto K
Ther Innov Regul Sci; 2019 Jul; 53(4):472-480. PubMed ID: 30157674
[TBL] [Abstract][Full Text] [Related]
17. STAKEHOLDERS' PERCEPTIONS OF HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
Ozturk K; Karadayı B; Şener O
Int J Technol Assess Health Care; 2018 Jan; 34(1):97-104. PubMed ID: 29151380
[TBL] [Abstract][Full Text] [Related]
18. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
[No Abstract] [Full Text] [Related]
19. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
20. HEALTH TECHNOLOGY ASSESSMENT EVIDENCE ON E-HEALTH/M-HEALTH TECHNOLOGIES: EVALUATING THE TRANSPARENCY AND THOROUGHNESS.
Vukovic V; Favaretti C; Ricciardi W; de Waure C
Int J Technol Assess Health Care; 2018 Jan; 34(1):87-96. PubMed ID: 29455685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
